Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

A Study of Personalized Neoantigen Cancer Vaccines

ClinicalTrials.gov ID: NCT03794128

Public ClinicalTrials.gov record NCT03794128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine and Screening Study for a Shared Neoantigen Cancer Vaccine in Patients With Advanced Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible for a shared neoantigen cancer vaccine where their tumor contains a specific shared mutation and who have the correct HLA allele capable of presenting the neoantigen derived from the tumor-specific mutation.

Study identification

NCT ID
NCT03794128
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Gritstone bio, Inc.
Industry
Enrollment
93 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 24, 2018
Primary completion
Jan 16, 2020
Completion
May 25, 2020
Last update posted
Sep 10, 2020

2018 – 2020

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
University of Chicago Medicine Comprehensive Cancer Center Chicago Illinois 60637
Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center New York New York 10032
The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Tennessee Oncology Nashville Tennessee 37203
Virginia Cancer Specialists Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Colorectal Cancer trials

Other public records listing Colorectal Cancer. Sorted by last update posted; newest first. Not a recommendation.

All Colorectal Cancer trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03794128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 10, 2020 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03794128 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →